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Abstract
Background: Common genetic variants in the PCSK9 gene have been reported to be associated
with both elevated and exceptionally low LDL levels. The association of a common haplotype,
encompassing the E670G single nucleotide polymorphism, with LDL levels reported by Chen et al
(J Am Coll Cardiol 2005; 45: 1644) was not confirmed by Kotowski et al (Am J Hum Genet 2006;
78:410–422).
Methods: The incidence of the E670G SNP was determined in 506 patients attending the lipid
clinic, University Hospital, Hamburg.
Results: The frequency in men with polygenic hypercholesterolemia, 0.11 was significantly higher
than in men with LDL<50th percentile, 0.03, p = 0.01. In women there was no difference in the allele
frequencies between the two groups.
Conclusion: In a European population the E670G SNP in the PCSK9 gene is associated with
increased LDL in men but not in women.
Background
Elevated plasma LDL is recognised as a major risk factor
for the development of atherosclerosis and coronary vas-
cular disease [1]. Mutations in the LDLR and APOB genes
are well established as monogenetic causes of familial
hypercholesterolemia (FH) and familial defective apoB
(FDB) respectively [2]. These conditions are characterised
by elevated LDL and increased risk of CVD. More recently
mutations in the PSCK9 gene [3] have been identified as
the cause of a third monogenetic form of famiial hyperc-
holesterolemia (FH3). However monogenetic hypercho-
lesterolemia represents only a small proportion of
patients with elevated LDL, in most cases hypercholester-
olemia is thought to be the result of a combination of die-
tary and genetic factors and is refered to as polygenic
hypercholesterolemia.
Since mutation in the PCKS9 gene can lead to monogenic
hypercholesterolemia, it is possible that common genetic
variation in the gene may contribute to polygenic hyperc-
holesterolemia. Through sequencing the PCSK9 gene of
probands with LDL below the 5th and above the 95th per-
centile, Kotowski et al [4] described a spectrum of variants
which contribute to plasma levels of LDL. They found var-
iants which were associated with low LDL and others
which were associated with elevated LDL. Chen et al [5]
performed a haplotype analysis of the PCSK9 gene in sub-
jects taking part in the LCAS study. They identified a hap-
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lotype, characterised by the G allele of the 23968A>G
(E670G) SNP, which was associated with increased LDL
levels and confirmed their observation in probands from
the TexGen study representing a normal population
(mean LDL 108 mg/dl). In contrast, Kotowski et al [4]
found no association of this SNP with LDL levels in sub-
jects taking part in the Dallas Heart Study, also a popula-
tion based study from Texas. The association of the IVS1-
161C>T and I475V SNPs with lower LDL reported in Jape-
nese subjects by Shioji et al. [6] could not be confirmed by
Kotowski et al [4].
In this study we determine the incidence of the 23968A>G
(E670G) polymorphism in the PCSK9 gene in patients
attending the lipid outpatients clinic of the University
Hospital in Hamburg. Given the conflicting reports
between American and Japenese populations, we
consdered it worthwhile to ascertain the role, if any, of
this SNP in polygenic hypercholesterolemia in a European
population. We reasoned that if this variant does indeed
cause an increase in LDL then it should show a higher fre-
quency amongst patients with polygenic hypercholestero-
lemia.
Methods
Patients
Patients were selected from those who attended the lipid
outpatient clinic, Universitätsklinikum Hamburg-Eppen-
dorf between 1997 and 2005. Informed consent was
obtained and the study was approved by the local ethics
commission. At the patients first visit a detailed case his-
tory was taken and biochemical and biometric values
were determined. The patients had a 30–60 minute ses-
sion with a dietician who discussed their normal diet and
gave dietary advice. Existing therapy was, where possible,
discontinued and at a second visit approximately 6 weeks
later biochemical and biometric values were again deter-
mined to provide data under diet/absence of drug ther-
apy. Only patients from whom lipid values obtained at
this second visit, i.e. after the diet advice and in the
absence of lipid lowering therapy were included in the
study and it is this lipid value we use in our analysis. In
order to eliminate patients with combined hyperlipi-
demia, patients with triglycerides above 200 mg/dl were
excluded. A total of 506 patients were included. The clin-
ical characteristics of the patients are presented in Table 1.
Biochemical measurements
Plasma cholesterol (TC) and triglycerides (TG) were deter-
mined using the GPO-PAP and CHOD-PAP kits respec-
tively from Boehringer Mannheim. HDL cholesterol was
determined following precipitation of apo B containing
lipoproteins with phosphotungstate (Boehringer Man-
nheim).
Genotyping
DNA was extracted using QIAamp DNA Blood mini kits
from Qiagen following the manufacturer's protocol. For
the determination of the frequency of the 23968A>G
(E670G) polymorphism a 167 bp DNA fragment was
obtained following PCR with the following primers: for-
ward primer: TACGCCGTAGACAACACG; reverse primer:
TCCCCAGACACCCATCCTGG. Digestion with mnlI
results in fragments of 100 bp and 67 bp for the common
A allele. Carriers of the variant G allele were confirmed by
digestion with sau96I.
Statistical methods
Allele frequencies were determined by gene counting and
compared using Fisher's exact test. Continuous variables
were compared using the Mann Whitney test. A p value of
0.05 or below was considered statistically significant.
Analysis was performed using Statistica software.
Results
The frequency of the G allele was 0.05 (AA 458, AG 45,
GG 3) which lies between that observed in the TexGen
population, 0.044 (AA 291, AG 28, GG 0) and that
reported for the LCAS study, 0.074 (AA 324, AG 41, GG 7)
by Chen et al in their original study. There was no statisti-
cal significant difference in the frequency of the G allele in
patients with LDL below the 50th percentile for age and
sex, 0.044 (AA 93, AG 9, GG 0), those with LDL between
the 50th and 95th percentiles 0.064 (AA 160, AG 20, GG 1)
and those with LDL above the 95th percentile, 0.064 (AA
205, AG 26, GG 2). Patients with LDL above the 95th per-
centile form a mixed group consisting of probands with
monogenic hypercholesterolemia and those with poly-
genic hypercholesterolemia. Nearly all cases of FDB are
the result of the APOB R3500Q mutation. Therefore the
incidence of this mutation was determined in all the
probands and eight patients were found to be carriers of
the variant. Assuming that an LDL level above 300 mg/dl
allows a diagnosis of familial hypercholesterolemia with
95% probability, 56 patients, 3 of whom were APOB3500
carriers fall into this group. The frequency of the G allele
Table 1: Clinical characteristics of the patients
M/F 239/267
Age (years) 44 (14)
BMI (kg/m2) 25 (3.7)
Total cholesterol (mg/dl) 270 (79)
LDL (mg/dl) 194 (77)
HDL (mg/dl) 53 (17)
Triglycerides (mg/dl) 120 (40)
Lipoprotein (a) (mg/dl) 26 (32)
Hypertension (n) 98
Type 2 diabetes (n) 10
Coronary heart disease (n) 48
For continuous variables values are means (SD)BMC Medical Genetics 2006, 7:66 http://www.biomedcentral.com/1471-2350/7/66
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was 3/56 probands with LDL>300 mg/dl and 1/8 APOB
3500 heterozygotes. Removing these patients with proba-
ble monogenic hypercholesterolemia from the group of
those with LDL above the 95th percentile results in an
increase in the frequency of the G allele in the remaining
probands with polygenic hypercholesterolemia to 0.076
(AA 148, AG 22, GG 2), which although higher than that
seen in patients with LDL below the 50th percentile the dif-
ference is not statistically significant. Power to detect dif-
ference between polygenic hypercholesterolemia and
LDL<50th percentile is 0.22.
Analysing the allele frequencies for men and women sep-
arately a different picture emerges (Fig. 1). In men the fre-
quency of the G allele in patients with LDL below the 50th
percentile is significantly lower than in patients with LDL
above the 95th percentile, 0.03 vs. 0.09, p = 0.05. The fre-
quency in patients with LDL between the 50th and 95th
percentiles (0.054) was intermediate. When the probands
with monogenic FH are excluded, the G allele frequency
in at 0.11 higher still and is of increased statistical signifi-
cance, p = 0.01. In contrast there is no association between
G allele frequency and hypercholesterolemia in women.
Mean lipid values according to 23968A>G (E670G) geno-
type are presented in Table 2. Table 2A shows the data for
all patients and in Table 2B the values when the probands
with monogenic hypercholesterolemia are omitted is pre-
sented. Although there is a suggestion that the G allele is
associated with increased LDL in men this was not statis-
tically significant. In women we observed no association
between E670G genotype and lipid levels. For neither sex
did we observe an association between the SNP and Lp(a)
as reported by Chen et al [5].
Discussion
The G allele of the E670G SNP in the PCSK9 gene was
present at an increased frequency in men, but not women,
Frequency of the G allele of the 23968A>G (E670G) SNP in the PCSK9 gene according to LDL levels Figure 1
Frequency of the G allele of the 23968A>G (E670G) SNP in the PCSK9 gene according to LDL levels. Probands 
were grouped into below the 50th percentile of LDL for age and sex, 50th–95th percentile and above the 95th percentile. In Pol 
Hchol are included probands with LDL above the 95th percentile for age and sex but had neither LDL above 300 mg/dl nor 
were heterozygous for the R3500Q mutation in the APOB gene. The number of patients in each group is indicated.
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with polygenic hypercholesterolemia thus partly confirm-
ing the findings of Chen et al [5]. The majority of the
probands in the LCAS study were men (310 out of 372)
and in the TexGen study, two thirds of the probands were
male (210 from 319), they did not separately analyse the
incidence of the SNP for men and women accounting for
their failure to observe a sex difference in the role of the
SNP. The Dallas Study provides no information on the
influence of sex on the effect of the SNP on lipid levels [4].
Whereas Chen et al [5] performed an extensive haplotype
analysis we have only investigated the association with
the E670G SNP which Chen et al [5] utilized as marker for
the haplotype associated with LDL levels, if the haplotype
structure were to be significantly different in our popula-
tion this could account for differences in our findings.
Since the mechanism by which variation in the PCSK9
gene affects LDL levels is unknown [4,5] we have no
explanation for the different effect of such variation
between men and women. We did not observe a signifi-
cant affect of the SNP on LDL levels. This is not unex-
pected since we were investigating a hyperlipidemic
population and since elevated LDL can be the result of
common genetic variants in a number of candidate genes
we would probably not detect a modest effect in this pop-
ulation.
Conclusion
We present evidence that a common genetic variant in the
PCSK9  gene contributes to polygenic hypercholestero-
lemia in men of European origin.
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